Shanghai Sundise Modern Traditional Chinese Medicine Co, Ltd. was reorganized and renamed as Shanghai Baheal Pharmaceutical Co., Ltd.

The company acquired Qingdao Baiyang Pharmaceutical Co., Ltd., which is characterized by slow-release preparation technology.

Baheal Pharma increased its stake and became the actual controlling shareholder of Shangha Sundise Modern Chinese Medicine Co, LtdIn the same year, Fuzheng Huayu won the "clinical value of Chinese patent medicine brand list".

Fuzheng Huayu, as an exclusive variety, entered the national list of essential drugs. In the same year, Huanghai Pharmaceutical became the deputy director unit of the Intelligent Manufacturing Committee of the Chinese Medicine Association.

Fuzheng Huayu was named "Shanghai Famous Brand Product", and its Shuanghai brand was awarded "Shanghai Famous Brand".

National Development and Reform Commission "Fuzheng Huayu capsule high-tech industrialization demonstration project" project completion acceptance.

In July, the company successfully acquired Anhui Zhihetang. Completed the construction of the whole modern Chinese medicine industry chain "from farmland to bedside". In November, the company released the "US phase II clinical research results”in Diaoyutai, Beijing, which became the only anti-fibrosis traditional Chinese patent medicines who has completed clinical treatment in the United States.

Fuzheng Huayu related patent "a traditional Chinese medicine compound preparation for the treatment of chronic liver disease and its preparation method" won the "China Patent Excellence Award".

Pinggan Fang (Fuzheng Huayu Tablets) received a new drug certificate from Hong Kong. Fuzheng Huayu related two patents authoried by the United States Patent Office (USPTO). Qishe Pill related project "Basic Research and Clinical Application of Yiqi Huayu Treatment for Lumbar Intervertebral Disc Degeneration Disease" won the second prize of National Science and Technology Progress Award.

The company completed the shareholding reform and changed its name to Shanghai Sundise Modern Chinese Medicine Co., Ltd.

Fuzheng huayu into the national health insurance directory. The company and the fourth generation of Shi's traumatology, Professor Shi Qi, a master of Chinese medicine, jointly innovated the treatment of nerve root cervical spondylosis, Qi Shewan, obtained the national new drug certificate.

The Phase II clinical trial of Fuzheng Huayu Tablets was approved by the U.S. FDA as the first liver disease Chinese patent medicine, and clinical research was conducted in eight first-line liver disease centers and hospitals in the United States.

Fuzheng Huayu Tablets "obtained the national new drug certificate.

The collaborative innovation achievement of the company and Shanghai University of Traditional Chinese Medicine "Application of Fuzheng Huayu Prescription in Anti-Hepatic Fibrosis Treatment and Related Basic Research" won the second prize of National Science and Technology Progress Award. In the same year, "Fuzheng Huayu Capsule" as a result of high-tech transformation, access to the national new drug certificate.

Huanghai Pharmaceutical has passed the national GMP certification and has been approved as a national high-tech enterprise.

The company has acquired Shanghai Huanghai Pharmaceutical Factory with zero assets and established a collaborative innovation system that runs through industry, academia, research and medicine.

Shanghai New Changning Group, Shanghai University of Traditional Chinese Medicine and East China University of Science and Technology invested in the establishment of Shanghai Modern Chinese Medicine Technology Development Co., Ltd. The company first promoted the concept of "modern Chinese medicine", with the mission of "modernization, standardization and internationalization of Chinese medicine", focusing on breakthroughs in the blank field of difficult treatment.